| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10063597 | The Breast | 2018 | 6 Pages |
Abstract
TNBC subgroup has the highest frequency of NY-ESO-1+ cases, and it could be the candidate population for the development of anti-NY-ESO-1 vaccine, both in the adjuvant or metastatic setting, and for the selection of cases suitable for immunotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Anna Tessari, Lorenzo Pilla, Damian Silvia, Matteo Duca, Biagio Paolini, Maria Luisa Carcangiu, Luigi Mariani, Filippo G. de Braud, Sara Cresta,